Literature DB >> 10456942

B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.

T L McCool1, C V Harding, N S Greenspan, J R Schreiber.   

Abstract

Conjugation of various serotypes of pneumococcal polysaccharide (PnPS) to carrier protein enhances the magnitude of the polysaccharide-specific antibody response, presumably by eliciting T-cell help. However, variability in PnPS serotype-specific immunogenicity has been observed. CBA/J mice immunized with either 6B or 19F PnPS conjugated to the protein carrier Cross Reactive Material(197) (CRM(197)) produce a strong anti-PnPS antibody response; however, when mice are immunized with 23F PnPS conjugated to CRM(197), they fail to produce a significant anti-PnPS response. In order to determine whether this difference was related to alterations in antigen processing of the carrier protein and the subsequent T-cell responses, we studied proliferation of lymphocytes from CBA/J mice immunized with CRM(197) alone or conjugated to 6B, 19F, or 23F PnPS. T-cell proliferative responses to synthetic peptides demonstrated that lymph node cells elicited by the poorly immunogenic conjugate 23F-CRM(197) recognized many, but not all, of the epitopes recognized by lymph node cells elicited by 6B- and 19F-CRM(197) as well as additional epitopes. Despite marked differences in PnPS-specific immunogenicity, all mice made high titers of CRM(197) antibodies of the immunoglobulin G(1) isotype. Cells from mice immunized with any of the conjugates yielded vigorous T-cell responses to whole antigen. We conclude that the serotype of PnPS can alter the peptide specificities of T-cell responses, but even a poorly immunogenic PnPS conjugate can elicit a significant T-cell response. Thus, conjugation of PnPS to a carrier protein that elicits carrier-specific T- and B-cell responses does not necessarily enhance PnPS immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456942      PMCID: PMC96820     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules.

Authors:  C V Harding; R W Roof; P M Allen; E R Unanue
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

2.  Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.

Authors:  R Austrian
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

3.  Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

Authors:  M B Rennels; K M Edwards; H L Keyserling; K S Reisinger; D A Hogerman; D V Madore; I Chang; P R Paradiso; F J Malinoski; A Kimura
Journal:  Pediatrics       Date:  1998-04       Impact factor: 7.124

4.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

Authors:  O T Avery; W F Goebel
Journal:  J Exp Med       Date:  1929-09-30       Impact factor: 14.307

5.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.

Authors:  L J Rubinstein; K E Stein
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

7.  Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny.

Authors:  L J Rubinstein; K E Stein
Journal:  J Immunol       Date:  1988-12-15       Impact factor: 5.422

8.  IgG and IgM pneumococcal polysaccharide antibody responses in infants.

Authors:  D J Barrett; C G Lee; A J Ammann; E M Ayoub
Journal:  Pediatr Res       Date:  1984-11       Impact factor: 3.756

Review 9.  Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenzae type B (Hib) conjugate vaccine.

Authors:  G S Bixler; R Eby; K M Dermody; R M Woods; R C Seid; S Pillai
Journal:  Adv Exp Med Biol       Date:  1989       Impact factor: 2.622

10.  Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. A redefinition of the TI-2 vs T cell-dependent antigen dichotomy.

Authors:  C M Snapper; M R Kehry; B E Castle; J J Mond
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

View more
  22 in total

1.  CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies.

Authors:  R S Chu; T McCool; N S Greenspan; J R Schreiber; C V Harding
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

Review 2.  Carbohydrate-based cancer vaccines: target cancer with sugar bullets.

Authors:  Chang-Cheng Liu; Xin-Shan Ye
Journal:  Glycoconj J       Date:  2012-06-06       Impact factor: 2.916

3.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  Intratracheal and intranasal immunization with ovalbumin conjugated with Bacillus firmus as a carrier in mice.

Authors:  P Mlcková; M Polácek; D Cechová; L Marusková; I Stanková; P Chalupná; O Novotná; J Julák; L Prokesová
Journal:  Folia Microbiol (Praha)       Date:  2005       Impact factor: 2.099

5.  Human monoclonal antibodies against Pseudomonas aeruginosa lipopolysaccharide derived from transgenic mice containing megabase human immunoglobulin loci are opsonic and protective against fatal pseudomonas sepsis.

Authors:  S Hemachandra; K Kamboj; J Copfer; G Pier; L L Green; J R Schreiber
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

6.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

7.  Limited role of antibody in clearance of Streptococcus pneumoniae in a murine model of colonization.

Authors:  Tera L McCool; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Enhanced immunogenicity of pneumococcal surface adhesin A by genetic fusion to cytokines and evaluation of protective immunity in mice.

Authors:  Dennis O Gor; Xuedong Ding; Qing Li; John R Schreiber; Michael Dubinsky; Neil S Greenspan
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

9.  Genetic variation influences the B-cell response to immunization with a pneumococcal polysaccharide conjugate vaccine.

Authors:  T L McCool; J R Schreiber; N S Greenspan
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine.

Authors:  Elizabeth A Clutterbuck; Sarah Oh; Mainga Hamaluba; Sharon Westcar; Peter C L Beverley; Andrew J Pollard
Journal:  Clin Vaccine Immunol       Date:  2007-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.